Diagnostic Platform

Retinal Amyloid Detection

A non-invasive window into Alzheimer's disease — years before symptoms appear.

Why It Matters

The Eye as a Biomarker for the Brain

Alzheimer's disease begins silently — amyloid plaques accumulate in the brain for a decade or more before the first cognitive symptom emerges. By the time a diagnosis is made, irreversible neuronal damage has already occurred. Earlier detection is not just clinically valuable; it is essential to any meaningful intervention.

The retina offers a unique and accessible window into the central nervous system. As a direct extension of the brain, the retina shares the same embryonic origin and vascular architecture. Critically, amyloid beta — the hallmark protein of Alzheimer's pathology — deposits in the retina in parallel with its accumulation in the brain, making retinal imaging a powerful proxy for cerebral amyloid burden.

Illustrative diagram of retinal amyloid detection

The Science

How Amyloid Appears in the Retina

Amyloid beta (Aβ) plaques have been identified in the retinas of Alzheimer's patients at densities that correlate with brain plaque load and disease severity. These deposits are spatially distributed across retinal layers and can be visualized using specialized optical imaging techniques — without the need for radioactive tracers, lumbar puncture, or MRI.

Progenicyte's platform leverages this biology by applying proprietary imaging and signal-processing methods to detect and quantify retinal amyloid with high sensitivity. The approach is grounded in peer-reviewed research demonstrating that retinal amyloid burden tracks with established cerebrospinal fluid and PET-based biomarkers of Alzheimer's pathology.

Clinical Advantages

A Better Path to Early Diagnosis

Non-Invasive

No radioactive tracers, no lumbar puncture, no MRI. Retinal imaging is performed with an ophthalmic-grade scanner in a standard clinical setting.

Earlier Detection

Retinal amyloid accumulates in parallel with brain pathology — enabling detection at preclinical stages, years before cognitive decline.

Lower Cost

Compared to amyloid PET scans (which can exceed $5,000) or CSF biomarker testing, retinal imaging offers a dramatically more accessible screening pathway.

Scalable Screening

The platform is designed for integration into ophthalmology and primary care workflows, enabling population-level screening at scale.

Objective & Quantitative

Proprietary image analysis produces a quantitative amyloid burden score, reducing diagnostic subjectivity and enabling longitudinal monitoring.

Complementary to Therapeutics

As disease-modifying therapies emerge, a low-cost screening tool becomes essential for identifying eligible patients and monitoring treatment response.

Our Platform

Progenicyte's Retinal Imaging Technology

Progenicyte has developed a proprietary retinal amyloid detection platform that combines advanced optical imaging with AI-driven image analysis to identify and quantify amyloid deposits in the retina. The system is designed to be deployed in clinical environments without specialized infrastructure, lowering the barrier to widespread adoption.

Our platform is being developed in close collaboration with academic research partners and validated against established gold-standard biomarkers. The technology is intended to serve both as a standalone screening tool and as a companion diagnostic for Alzheimer's therapeutics — including Progenicyte's own APC-100 program.

Development Stage

Where We Are

Preclinical ValidationComplete

Retinal amyloid detection validated in animal models and post-mortem human tissue studies.

Platform DevelopmentIn Progress

Proprietary imaging hardware and AI analysis pipeline under active development and refinement.

Clinical Feasibility StudyPlanned

Planned first-in-human feasibility study to validate detection sensitivity and specificity against PET and CSF benchmarks.

Regulatory PathwayPlanned

Pre-submission engagement with FDA to define the regulatory pathway for De Novo or 510(k) clearance as a diagnostic device.

CommercializationPlanned

Targeted deployment through ophthalmology networks, memory clinics, and primary care partnerships.

Supporting Research

Grounded in Peer-Reviewed Science

Koronyo-Hamaoui M, et al. (2011). Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model.

NeuroImage2011

Koronyo Y, et al. (2017). Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.

JCI Insight2017

Hart NJ, et al. (2016). Large-scale retinal imaging reveals amyloid-beta deposits in the retinas of Alzheimer's disease patients.

Acta Neuropathologica2016

Snyder PJ, et al. (2021). Retinal imaging in Alzheimer's and neurodegenerative diseases.

Alzheimer's & Dementia2021

Partner With Us

We are actively seeking research collaborators, clinical partners, and investors to accelerate the development and deployment of our retinal amyloid detection platform. If you are interested in advancing early Alzheimer's diagnostics, we would welcome the conversation.

Contact Us